[Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease].
BACKGROUND
Macrophage activation syndrome has never been reported as an adverse effect of infliximab.


METHODS
Treatment with infliximab was prescribed for a 37-year-old man with fistulated Crohn's disease unresponsive to azathioprine. Three months after the last injection, he developed macrophagic activation syndrome, with febrile pancytopenia, hyperferritinemia, hypertriglyceridemia and an activated cephalin time twice the control level.


CONCLUSIONS
Elimination of the known causes of macrophage activation syndrome suggests it is related to the infliximab treatment, but its pathogenesis remains a mystery.
Chauveau
Eric
E
Service des maladies digestives et tropicales, Hôpital d'Instruction des Armées Robert Picqué 33998 Bordeaux Armées.
Terrier
François
F
Casassus-Buihle
Didier
D
Moncoucy
Xavier
X
Oddes
Bernard
B
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D003424:Crohn Disease / Q000188:drug therapy*; D005293:Ferritins / Q000097:blood; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015228:Hypertriglyceridemia / Q000139:chemically induced; D000069285:Infliximab; D008262:Macrophage Activation / Q000187:drug effects*; D008297:Male; D010198:Pancytopenia / Q000139:chemically induced; D010587:Phagocytosis; D013577:Syndrome
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D005293:Ferritins; D000069285:Infliximab